SEARCH

SEARCH BY CITATION

References

  • 1
    Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797810.
  • 2
    Hohlfeld R, Toyka KV, Heininger K, Grosse-Wilde H, Kalies I. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 1984; 310: 2446.
  • 3
    Sommer N, Harcourt GC, Willcox N, Beeson D, Newsom-Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 1991; 41: 12706.
  • 4
    Vincent A, Willcox N. The role of T-cells in the initiation of autoantibody responses in thymoma patients. Pathol Respiract 1999; 195: 53540.
  • 5
    Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 1832.
  • 6
    Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 81622.
  • 7
    Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 130310.
  • 8
    Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004; 59: 198202.
  • 9
    Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003; 33: 21523.
  • 10
    Kukreja A, Cost G, Marker J et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 13140.
  • 11
    Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 9719.
  • 12
    Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+) CD25(+) T cells in tumours from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 476672.
  • 13
    Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumour microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 275661.
  • 14
    Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 60612.
  • 15
    Fattorossi A, Battaglia A, Ferrandina G, Coronetta F, Legge F, Salutari V, Scambia G. Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 2004; 100: 141828.
  • 16
    Huang YM, Pirskanen R, Giscombe R, Link H, Lefvert AK. Circulating CD4+CD25+ and CD4+CD25+Tcells in myasthenia gravis and in relation to thymectomy. Scand J Immunol 2004; 59: 40814.
  • 17
    Battaglia A, Di Schino C, Fattorossi A, Scambia G, Evoli A. No evidence for alterations in circulating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: a flow cytometry study. J Biol Regul Homeost Agents 2005; in press.
  • 18
    Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S. Thymus and autoimmunity. production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162: 531726.
  • 19
    Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+) CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001; 31: 124754.
  • 20
    Wing K, Ekmark A, Karlsson H, Rudin A, Suri-Payer E. Characterization of human CD25+CD4+ T cells in thymus, cord and adult blood. Immunology 2002; 106: 1909.
  • 21
    Annunziato F, Cosmi L, Liotta F et al. S. Phenotype, localization, and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 2002; 196: 37987.
  • 22
    Cosmi L, Liotta F, Lazzeri E et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003; 102: 410714.
  • 23
    Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation. Neurology 2000; 55: 1623.
  • 24
    Evoli A, Minisci C, Di Schino C et al. L. Thymoma in patients with MG. Characteristics and long-term outcome. Neurology 2002; 59: 184450.
  • 25
    Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E. Clinical correlates with anti-Musk antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 230411.
  • 26
    Pacifici R, Zuccaro P, Cozzi-Lepre A, Di Carlo S, Bacosi A, Fattorossi A. Quantification of the variation due to lysing technique in immunophenotyping of healthy and HIV-infected individuals. Clin Biochem 1998; 31: 16572.
  • 27
    Rocca B, Maggiano N, Habib A et al. Distinct expression of cyclooxygenase-1 and -2 in the human thymus. Eur J Immunol 2002; 32: 148292.
  • 28
    Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 2001; 167: 124553.
  • 29
    Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+) CD25(+high) regulatory T cell function. J Immunol 2002; 169: 621017.
  • 30
    Fattorossi A, Battaglia A, Malinconico P et al. Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells. Exp Cell Res 2002; 280: 10718.
  • 31
    Battaglia A, Ferrandina G, Buzzonetti A, Malinconico P, Legge F, Salutari V, Scambia G, Fattorossi A. Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vβ repertoire. Immunology 2003; 110: 30412.
  • 32
    Levings MK, Sangregorio R, Roncarolo MG. Human CD25(+) CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295302.
  • 33
    Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+) CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 128594.
  • 34
    Brunelli R, Frasca D, Baschieri S et al. Changes in thymocyte subsets induced by estradiol administration or pregnancy. Ann N Y Acad Sci 1992; 650: 10914.
  • 35
    Balandina A, Saoudi A, Dartevelle P, Berrih-Aknin S. Analysis of CD4+CD25+ cell population in the thymus from myasthenia gravis patients. Ann NY Acad Sci 2003; 998: 2757.
  • 36
    Muller-Hermelink HK, Wilisch A, Schultz A, Marx A. Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Arch Histol Cytol 1997; 60: 928.
  • 37
    Muller-Hermelink HK, Marx A. Thymoma. Curr Opin Oncol 2000; 12: 42633.
  • 38
    Strobel P, Preisshofen T, Helmreich M, Muller-Hermelink HK, Marx A. Pathomechanisms of paraneoplastic myasthenia gravis. Clin Dev Immunol 2003; 10: 712.
  • 39
    Jamieson BD, Douek DC, Killian S et al. Generation of functional thymocytes in the human adult. Immunity 1999; 10: 56975.
  • 40
    Sempowski GD, Thomasch JR, Gooding ME et al. Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. J Immunol 2001; 166: 280817.
  • 41
    Somnier FE. Exacerbation of myasthenia gravis after removal of thymomas. Acta Neurol Scand 1994; 90: 5666.
  • 42
    Bluestone J, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 2537.
  • 43
    Akbar AN, Taams LS, Salmon M, Vukmanovic-Stejic M. The peripheral generation of CD4+ CD25+ regulatory T cells. Immunology 2003; 109: 31925.
  • 44
    Groux H, Fournier N, Cottrez F. Role of dendritic cells in the generation of regulatory T cells. Semin Immunol 2004; 16: 99106.
  • 45
    Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur J Immunol 2000; 30: 123342.
  • 46
    Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 2434.
  • 47
    Canning MO, Grotenhuis K, De Wit HJ, Drexhage HA. Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells. Eur J Endocrinol 2000; 143: 68795.
  • 48
    Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 194553.
  • 49
    Barrat FJ, Cua DJ, Boonstra A et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1- (Th1) and Th2-inducing cytokines. J Exp Med 2002; 195: 60316.